FathomX announces that the Singapore Health Sciences Authority, HSA, recently approved FxMammo™, the digital AI imaging solution for diagnosing breast cancer, developed by FathomX. The approval demonstrates that using an AI assistant as an adjunct in diagnosis of breast cancer, together with a radiologist, generates an accurate, reliable and consistent diagnosis of cancer.
FxMammo™ is HSA-approved as a radiological computer-assisted detection and diagnostic software to aid in the detection of breast cancer on acquired mammography images. The software detects and identifies suspicious breast cancer cases based on features or information extracted from the images. FxMammo™ is intended as an adjunct tool for physicians.
FxMammo™ was one of six innovations, from originally 256 applications, which were awarded a total of $2.4 million at the recent Healthcare InnoMatch 2022, organised by the Centre for Healthcare Innovation (CHI) and supported by the Ministry of Health (MOH) and Temasek Foundation (TF).
Healthcare InnoMatch is a global call for proposals from start-ups and small and medium-sized enterprises where all three public healthcare clusters in Singapore – National University Health System (NUHS), National Healthcare Group and Singapore Health Services – collaborate using a common competition framework. The winning projects will be able to take advantage of the experience of test bedding their innovations with a selected healthcare cluster, with following extension to all public healthcare clusters and future larger-scale implementation and commercialisation, in and beyond Singapore. Projects that are successfully test-bedded and adopted in the public healthcare clusters will benefit more patients and provide them with access to the latest solutions to improve their health outcomes.
The FxMammo™ will be piloted at the National University Hospital (NUH), which is a leading tertiary hospital under NUHS, in the first half of 2023.
“We welcome the approval by HSA. Breast cancer is the most common cancer in women and it is doubling in numbers by each generation in Asia. Successful treatment requires reliable diagnosis, which involves difficult to read mammograms. The need for a reliable, easy to access solution that addresses the low ratio of radiologists to mammography screening needs for breast cancer, is both urgent and tremendous.
As a winning project in Healthcare InnoMatch 2022, FxMammo™ will be test-bedded with at least one public healthcare cluster with the possibility to scale across the entire Singaporean health care system if successful. This will accelerate the development of our market-ready AI assistant for breast cancer diagnosis,”
said Asst Prof Feng Meng Ling and A/Prof Mikael Hartman, co-founders of FathomX.
Senior consultants Dr Premilla Pillay and Dr Pooja Jagmohan from the Department of Diagnostic Imaging, NUH, who will be leading the pilot at the hospital said, “This innovative AI solution could help overcome some of the limitations of diagnosing from mammography and would potentially be a useful tool for radiologists as it intends to enable radiologists to increase accuracy, allowing them to detect any abnormalities better and faster. It could also reduce the chance of getting false positive results from mammogram screenings and save many women from unnecessary anxiety.”
FathomX, a digital health AI spin-off company from the National University of Singapore and National University Health System, aims to develop a range of AI technologies in the field of breast cancer. The company develops knowledge, capabilities and value through collaborations with research and healthcare institutions, deployment and teleradiology partners as well as picture archiving and communication systems (PACS). FathomX recently received add-on investments from existing investors, leading up to launch of Series A funding intended for regional commercialisation and new product development.
For more information, visit www.fathomx.co